Two years away from clinical trials, the method targets the T-cell in the immune system - offering patients the possibility of a treatment beyond medication and its side effects. It also has the potential to be adapted for up to 100 other autoimmune conditions, affecting 10 per cent of the world's population.
Listen to SBS Indonesian every Monday, Wednesday, Friday, and Sunday at 3 pm.
